Abbott Finalizes Multi-Billion Dollar Acquisition of Exact Sciences

On March 23, 2026, the medical giant Abbott officially finalized its multi-billion dollar acquisition of Exact Sciences, a strategic move valued at approximately $23 billion.

This merger is set to position Abbott as a powerhouse in the growing fields of cancer screening and precision oncology.

As part of the agreement, Exact Sciences will function as a subsidiary while maintaining its home base in Madison, Wisconsin.

This acquisition allows Abbott to incorporate a prestigious product portfolio, including the well-known Cologuard for colorectal cancer screening and the Oncotype DX test for breast cancer treatment planning.

Industry experts note that this expansion will add roughly $3 billion to Abbott's annual sales.

CEO Robert B.

Ford emphasized that this transition represents a pivotal shift toward more predictive and personalized diagnostic healthcare.

By combining Exact Sciences' innovative technology with Abbott's massive global commercial network, the company aims to broaden international access to life-saving cancer tests.

While Kevin Conroy, the CEO of Exact Sciences, transitions into an advisory role, the industry watches closely to see how this deal will reshape the future of diagnostic medicine on a global scale.